MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

about

Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.Renal Injury during Long-Term Crizotinib Therapy

P2860

Q52361534-D3549246-E8E7-4E0D-AA4C-5DEF627991A4 Q59133910-1A439AA7-659E-4797-901C-0C4213700150

P2860

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Item

http://www.wikidata.org/entity/Q40064345

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

MET-GRB2 Signaling-Associated ...... vity to MET Kinase Inhibitors.

@en

type

Item

label

MET-GRB2 Signaling-Associated ...... vity to MET Kinase Inhibitors.

@en

prefLabel

MET-GRB2 Signaling-Associated ...... vity to MET Kinase Inhibitors.

@en

P1476

MET-GRB2 Signaling-Associated ...... vity to MET Kinase Inhibitors.

@en

P2093

Alain Borczuk

http://www.w3.org/2001/XMLSchema#string

Aliya Lakhani

http://www.w3.org/2001/XMLSchema#string

Balazs Halmos

http://www.w3.org/2001/XMLSchema#string

Ben C Creelan

http://www.w3.org/2001/XMLSchema#string

Eric B Haura

http://www.w3.org/2001/XMLSchema#string

Marileila Varella-Garcia

http://www.w3.org/2001/XMLSchema#string

Matthew A Smith

http://www.w3.org/2001/XMLSchema#string

Theresa A Boyle

http://www.w3.org/2001/XMLSchema#string

Thomas Licata

http://www.w3.org/2001/XMLSchema#string

Vincent Vuaroqueaux

http://www.w3.org/2001/XMLSchema#string

P2860

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

Comprehensive molecular profiling of lung adenocarcinoma.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

P31

scholarly article

P356

10.1158/1078-0432.CCR-16-3006

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Hans-Ulrich Schildhaus

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28855353

http://www.w3.org/2001/XMLSchema#string

P932

5833309

http://www.w3.org/2001/XMLSchema#string

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

about

P2860

P2860

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932